CD274 and non-small cell lung carcinoma: Considering that pembrolizumab and cemiplimab are comparatively new treatment for patients with advanced NSCLC with high PD-L1 expression, long-term follow-up survival data were not reported, and the accuracy of the results of our study could not be further validated and explored.